ArticleBMC biotechnology2026
Berberine-ZnO loaded chitosan nanoparticles inhibits biofilm formation in Pseudomonas aeruginosa PAO1 through targeting extracellular polymeric substances.
Article in BMC biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBiofilm formation is an important strategy for coping with antimicrobial agents and worsening bacterial infections. In this investigation, we synthesized berberine-zinc oxide-loaded chitosan nanoparticles (CS-ZnO-Ber NPs) and explored their potential as anti-biofilm agents against Pseudomonas aeruginosa PAO1.
resultsCS-ZnO-Ber NPs exhibited an amorphous structure with particle sizes ranging from 34.7 to 407.7 nm and a zeta potential of − 38.5 mV. The biofilm inhibitory activity of the fabricated NPs was validated using a crystal violet staining assay. Based on the SEM imaging, cells treated with NPs displayed thin biofilms with low aggregation, whereas the untreated group exhibited robust biofilms with dense architecture. Moreover, at sub-inhibitory concentration of CS-ZnO-Ber NPs, the production levels of extracellular matrix components, including exopolysaccharides, pellicle, and alginate, decreased by 92.81 ± 0.84%, 81.45 ± 3.1%, and 31.74 ± 2.91%, respectively. Additionally, exposure to CS-ZnO-Ber NPs resulted in a significant reduction in pyocyanin production and attenuation of bacterial motility, including swimming, swarming, and twitching. CS-ZnO NPs and CS-ZnO-Ber NPs also decreased the EtBr MIC four-fold and eight-fold, respectively, indicating their efflux pump–inhibitory activity. Furthermore, molecular docking simulations revealed a favorable binding orientation of berberine with biofilm-associated proteins (AlgD, PelD, and PslG), as well as with quorum-sensing regulators LasI and LasR.
conclusionOverall, CS-ZnO-Ber NPs substantially diminished extracellular matrix components, leading to the formation of weak and unstable biofilms. Pending further investigation, these findings suggest that CS-ZnO-Ber NPs hold promise as effective agents for controlling biofilm-related infections caused by P. aeruginosa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.